New model aims to perfect antibiotic dosing for sepsis in the ICU
NCT ID NCT03748095
First seen Jun 24, 2026 · Last updated Jun 30, 2026 · Updated 3 times
Summary
This study looked at 91 sepsis patients in intensive care to create a computer model that predicts the right dose of the antibiotic piperacillin/tazobactam. Researchers took blood samples at different times to measure drug levels. The goal was to develop a tool that helps doctors give the most effective and safe dose for each patient, reducing the risk of underdosing or side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
piperacillin/tazobactam (an antibiotic combination)
What this could lead to
If successful, this could lead to more personalized antibiotic dosing for sepsis patients in intensive care, potentially improving outcomes and reducing side effects.
What could go wrong
This is a small, completed modeling study, not a treatment trial. The model needs further validation before it can be used in practice, and results may not apply to all sepsis patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEPSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de Rouen
Rouen, France, France